Surface modification with PEG and hirudin for protein resistance and thrombin neutralization in blood contact

In this work, we hypothesize that a surface modified with both polyethylene glycol (PEG) and hirudin may provide a non-fouling, thrombin-neutralizing surface suitable for blood contacting applications. With gold as a model substrate we used two different approaches to the preparation of such a surface: (1) a "direct" method in which PEG was conjugated to hirudin and the conjugate was then immobilized on the gold; (2) a "sequential" method in which PEG was immobilized on the gold and hirudin then attached to the immobilized PEG. The surfaces were characterized by water contact angle, ellipsometry and XPS. The biological properties were investigated by measuring protein adsorption (fibrinogen and thrombin) from buffer and plasma; thrombin inhibition was measured using a chromogenic substrate assay. Hirudin immobilization was found to be more efficient on surfaces prepared by the "direct" method. "Sequential" surfaces, however, despite having a lower density of hirudin, showed greater biological activity (thrombin binding and inhibition).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

In this work, we hypothesize that a surface modified with both polyethylene glycol (PEG) and hirudin may provide a non-fouling, thrombin-neutralizing surface suitable for blood contacting applications.

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

More peer-reviewed studies in Arzneimittelentwicklung.

• Novel Leech Antimicrobial Peptides — Hirunipins — Kumar et al. (2025)
• Medicinal Leech Genome Assembly — Anticoagulant Gene Catalog — Kvist et al. (2020)
• BRIGHT-4 Trial — Bivalirudin vs Heparin by BMI — BRIGHT-4 Investigators (2025)
• RE-LY Trial — Dabigatran vs Warfarin in Atrial Fibrillation — Connolly SJ et al. (2009)
• Hirudin Disrupts Breast Cancer CTC Clusters — Anti-Metastatic Potential — Research team (2025) (2025)
• Novel CRA Protein from Hirudo medicinalis — Complement Regulation — Research team (2025) (2025)
• Hirunipin-2 — Second-Generation Leech Antimicrobial Peptide — Kumar et al. (2025)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• Hirudotherapy in Medicine and Dentistry — Jha K et al. (2015)
• Medicinal leech therapy (hirudotherapy): a brief overview — Singh A (2010)